» Articles » PMID: 14672670

Molecular Mechanisms for Viral Mimicry of a Human Cytokine: Activation of Gp130 by HHV-8 Interleukin-6

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2003 Dec 16
PMID 14672670
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV, or HHV-8) encodes a pathogenic viral homologue of human interleukin-6 (IL-6). In contrast to human IL-6 (hIL-6), viral IL-6 (vIL-6) binds directly to, and activates, the shared human cytokine signaling receptor gp130 without the requirement for pre-complexation to a specific alpha-receptor. Here, we dissect the biochemical and functional basis of vIL-6 mimicry of hIL-6. We find that, in addition to the "alpha-receptor-independent" tetrameric vIL-6/gp130 complex, the viral cytokine can engage the human alpha-receptor (IL-6Ralpha) to form a hexameric vIL-6/IL-6Ralpha/gp130 complex with enhanced signaling potency. In contrast to the assembly sequence of the hIL-6 hexamer, the preformed vIL-6/gp130 tetramer can be decorated with IL-6Ralpha, post facto, in a "vIL-6-dependent" fashion. A detailed comparison of the viral and human cytokine/gp130 interfaces indicates that vIL-6 has evolved a unique molecular strategy to interact with gp130, as revealed by an almost entirely divergent structural makeup of its receptor binding sites. Viral IL-6 appears to utilize an elegant combination of both convergent, and unexpectedly divergent, molecular strategies to oligomerize gp130 and activate similar downstream signaling cascades as its human counterpart.

Citing Articles

The Role of vIL-6 in KSHV-Mediated Immune Evasion and Tumorigenesis.

Komaki S, Inagaki T, Kumar A, Izumiya Y Viruses. 2025; 16(12.

PMID: 39772207 PMC: 11680145. DOI: 10.3390/v16121900.


Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis.

Li K, Cai J, Jiang Z, Meng Q, Meng Z, Xiao H Sci Rep. 2024; 14(1):18293.

PMID: 39112658 PMC: 11306327. DOI: 10.1038/s41598-024-69429-w.


KSHV vIL-6 enhances inflammatory responses by epigenetic reprogramming.

Inagaki T, Wang K, Kumar A, Izumiya C, Miura H, Komaki S PLoS Pathog. 2023; 19(11):e1011771.

PMID: 37934757 PMC: 10656005. DOI: 10.1371/journal.ppat.1011771.


Primary Effusion Lymphoma: A Clinicopathologic Perspective.

Gathers D, Galloway E, Kelemen K, Rosenthal A, Gibson S, Munoz J Cancers (Basel). 2022; 14(3).

PMID: 35158997 PMC: 8833393. DOI: 10.3390/cancers14030722.


Multicentric Castleman disease and the evolution of the concept.

Zhou T, Wang H, Pittaluga S, Jaffe E Pathologica. 2021; 113(5):339-353.

PMID: 34837092 PMC: 8720411. DOI: 10.32074/1591-951X-351.